Showing results (11-20 of 24) with videos related to
Sort By:
Pageof 3
Cell Death Discovery|October 6, 2025
Combination of HDAC inhibitor and PI3K inhibitor suppresses autophagy and induces apoptosis via cytoplasmic IκBα stabilization in p53-mutant diffuse large B-cell lymphomaJingwei Yao, Mengqi Li, Yuelong Jiang, et al.Experimental Hematology & Oncology|April 17, 2022
Therapeutic synergy of Triptolide and MDM2 inhibitor against acute myeloid leukemia through modulation of p53-dependent and -independent pathwaysQinwei Chen, Suqi Deng, Manman Deng, et al.Journal of Personalized Medicine|October 23, 2021
Therapeutic Interaction of Apatinib and Chidamide in T-Cell Acute Lymphoblastic Leukemia through Interference with Mitochondria Associated Biogenesis and Intrinsic ApoptosisMengya Zhong, Fusheng Lin, Yuelong Jiang, et al.Frontiers in Oncology|December 20, 2021
Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular LymphomaMengya Zhong, Jinshui Tan, Guangchao Pan, et al.Clinical Epigenetics|May 4, 2025
Venetoclax confers synthetic lethality to chidamide in preclinical models with transformed follicular lymphomaMengya Zhong, Guangchao Pan, Jinshui Tan, et al.European Journal of Pharmacology|November 29, 2021
Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulationLihong Ding, Qinwei Chen, Kai Chen, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|May 7, 2026
Rewiring NADH Metabolism Through NQO1-Mediated Redox Cycling for Targeted Follicular Lymphoma TherapyJinxing Zhang, Ziqi Wang, Ye Weng, et al.Experimental Hematology & Oncology|December 19, 2024
Chiglitazar diminishes the warburg effect through PPARγ/mTOR/PKM2 and increases the sensitivity of imatinib in chronic myeloid leukemiaHongpeng Duan, Qian Lai, Yuelong Jiang, et al.Frontiers in Oncology|March 29, 2021
CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With <i>MYC</i> and <i>BCL2</i> RearrangementsDelin Yuan, Genhong Li, Lian Yu, et al.Pharmaceuticals (Basel, Switzerland)|November 10, 2022
Preclinical Evaluation of the Multiple Tyrosine Kinases Inhibitor Anlotinib in Leukemia Stem CellsYuelong Jiang, Long Liu, Yirong Jiang, et al.Pageof 3